Version May 2024
| Test(s) | Company | List price* (USD) | Sample requirement | Clinical utility/intended use | Comments |
| Decipher Biopsy and Decipher Postoperative | Decipher Biosciences (formally Genome Dx) | $5150 | FFPE tissue from prostate biopsy, or | Categorize patients into low/high risk to stratify patients to surveillance versus treatment (and intensity of treatment) | Evaluates mRNA expression levels of 22 genes from FFPE tissue; generates score from 0 to 1.0 |
| Prostate tissue after RP | Postprostatectomy for patients with adverse pathologic features to guide whether surveillance, adjuvant therapy, or salvage therapy may be warranted | ||||
| Oncotype Dx GPS | Genomic Health | $4520 | Tumor tissue from original biopsy in neutral buffered formalin; prostatectomy specimens not accepted | Biopsy-based likelihood of adverse pathologic features (grade group ≥3 or extracapsular extension); identify those who may benefit from surveillance versus treatment | GPS ranges from 0 to 100 based on mRNA expression of 17 genes across 4 pathways |
| Prolaris Biopsy and Prolaris Postprostatectomy | Myriad Genetic Laboratories | $3900 | FFPE tissue from prostate tumor biopsy or prostatectomy specimens | Aggressiveness of cancer; provides a 10-year risk of metastasis after definitive therapy, and disease-specific mortality under conservative management | mRNA expression of cell-cycle progression genes is used to calculate the score; clinical factors are subsequently added for risk assessment |
| ProMark, Proteomic Prognostic test for prostate cancer | MetaMark | $3900 | Requires tissue collected with patented biopsy kit available from MetaMark | Uses automated image recognition technology to determine the likelihood of grade group ≥2 or stage ≥T3b | Expression of 8 proteins; uses automated image recognition technology to generate a score from 1 to 100 indicating the aggressiveness of prostate cancer |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
